<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006274.pub3" GROUP_ID="SYMPT" ID="714805092917394838" MERGED_FROM="" MODIFIED="2015-05-08 15:18:53 +0100" MODIFIED_BY="[Empty name]" REVIEW_NO="169" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.0">
<COVER_SHEET MODIFIED="2015-05-08 15:18:53 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2014-03-21 09:33:18 +0000" MODIFIED_BY="Anna Hobson">Medically assisted nutrition for adult palliative care patients</TITLE>
<CONTACT>
<PERSON ID="49B538D082E26AA2000C5DBB71393662" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Phillip</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Good</LAST_NAME>
<SUFFIX>MBBS FRACP FAChPM PhD</SUFFIX>
<POSITION>Senior Specialist</POSITION>
<EMAIL_1>Phillip.Good@svha.org.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Mater Research Institute &#8211; The University of Queensland</ORGANISATION>
<ADDRESS_1>411 Main Street</ADDRESS_1>
<ADDRESS_2>Kangaroo Point</ADDRESS_2>
<CITY>Brisbane</CITY>
<ZIP>4169</ZIP>
<REGION>Queensland</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+61 7 3240 1111</PHONE_1>
<PHONE_2/>
<FAX_1>+61 7 3240 1192</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2015-05-08 15:18:19 +0100" MODIFIED_BY="Anna Hobson">
<PERSON ID="49B538D082E26AA2000C5DBB71393662" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Phillip</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Good</LAST_NAME>
<SUFFIX>MBBS FRACP FAChPM PhD</SUFFIX>
<POSITION>Senior Specialist</POSITION>
<EMAIL_1>Phillip.Good@svha.org.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Mater Research Institute &#8211; The University of Queensland</ORGANISATION>
<ADDRESS_1>411 Main Street</ADDRESS_1>
<ADDRESS_2>Kangaroo Point</ADDRESS_2>
<CITY>Brisbane</CITY>
<ZIP>4169</ZIP>
<REGION>Queensland</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+61 7 3240 1111</PHONE_1>
<PHONE_2/>
<FAX_1>+61 7 3240 1192</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="z1312051401228969534178193205451" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Russell</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Richard</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>russell.richard@svha.org.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>St Vincent&#8217;s Private Hospital</ORGANISATION>
<ADDRESS_1>411 Main Street</ADDRESS_1>
<ADDRESS_2>Kangaroo Point</ADDRESS_2>
<CITY>Brisbane</CITY>
<ZIP/>
<REGION>Queensland</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>61732401337</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="z1312051403241318402735043495680" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>William</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Syrmis</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>william.syrmis@svha.org.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>St Vincent&#8217;s Private Hospital</ORGANISATION>
<ADDRESS_1>411 Main Street</ADDRESS_1>
<ADDRESS_2>Kangaroo Point</ADDRESS_2>
<CITY>Brisbane</CITY>
<ZIP/>
<REGION>Queensland</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>61732401165</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="15245" ROLE="AUTHOR">
<PREFIX>Ms</PREFIX>
<FIRST_NAME>Sue</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Jenkins-Marsh</LAST_NAME>
<SUFFIX/>
<POSITION>Research Manager</POSITION>
<EMAIL_1>suejenksman@hotmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>61431990290</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>The Townsville Hospital</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Townsville</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>61431990290</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="z1312051406540131899820005906445" ROLE="AUTHOR">
<PREFIX>Ms</PREFIX>
<FIRST_NAME>Jane</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Stephens</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>jane.stephens@svha.org.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>St Vincent&#8217;s Private Hospital</ORGANISATION>
<ADDRESS_1>411 Main Street</ADDRESS_1>
<ADDRESS_2>Kangaroo Point</ADDRESS_2>
<CITY>Brisbane</CITY>
<ZIP/>
<REGION>Queensland</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2014-04-17 11:21:36 +0100" MODIFIED_BY="Anna Hobson">
<UP_TO_DATE>
<DATE DAY="26" MONTH="3" YEAR="2014"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="26" MONTH="3" YEAR="2014"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="1" YEAR="2019"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2006"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2008"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2014"/>
</DATES>
<WHATS_NEW MODIFIED="2015-05-08 15:18:53 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="STABLE" MODIFIED="2015-05-08 15:18:53 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="8" MONTH="5" YEAR="2015"/>
<DESCRIPTION>
<P>This review will be assessed for further updating in 2019.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2015-05-08 15:18:35 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-05-08 15:18:35 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="16" MONTH="4" YEAR="2014"/>
<DESCRIPTION>
<P>Updated Review - we ran an updated search in April 2013 and March 2014, and included a PRISMA flowchart of the study selection process. </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2015-05-08 15:18:33 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="16" MONTH="4" YEAR="2014"/>
<DESCRIPTION>
<P>No trials fitted the inclusion criteria. The original review identified four prospective non-controlled trials, and a Cochrane review, and the updated search in 2014 identified one more prospective non-controlled trial and an updated Cochrane review. All five trials (plus Cochrane review) are discussed in this update. The conclusions from the original review remain unchanged.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2014-01-09 13:06:39 +0000" MODIFIED_BY="Anna Hobson">
<DATE DAY="11" MONTH="5" YEAR="2011"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-05-11 16:05:21 +0100" MODIFIED_BY="Jessica Thomas">
<DATE DAY="6" MONTH="10" YEAR="2010"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-10-06 16:56:25 +0100" MODIFIED_BY="Jessica Thomas">
<DATE DAY="30" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Minor edits made to text using new RevMan 5 software</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2014-04-02 09:32:57 +0100" MODIFIED_BY="Anne Lawson">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES MODIFIED="2014-04-02 09:32:57 +0100" MODIFIED_BY="Anne Lawson">
<SOURCE MODIFIED="2014-04-02 09:32:57 +0100" MODIFIED_BY="Anne Lawson">
<NAME>National Institute for Health Research (NIHR)</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>NIHR Directly Commissioned Cochrane Incentive Scheme 2013 (Award Reference Number: 13/180/03).</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2014-04-17 11:23:41 +0100" MODIFIED_BY="Anna Hobson">
<SUMMARY MODIFIED="2014-04-16 12:55:00 +0100" MODIFIED_BY="Anna Hobson">
<TITLE>Medically assisted nutrition to assist palliative care patients</TITLE>
<SUMMARY_BODY MODIFIED="2014-04-16 12:55:00 +0100" MODIFIED_BY="Anna Hobson">
<P>
<B>Background</B>
</P>
<P>It is common for palliative care patients to have reduced oral intake during their illness. Management of this condition includes discussion with the patient, family and staff involved, and may include giving nutrition with medical assistance. This can be done either via a plastic tube inserted directly into a vein or into the stomach or other parts of the gastrointestinal tract. It is unknown whether this treatment helps people to feel better or live longer.</P>
<P>
<B>Study characteristics</B>
</P>
<P>We searched the international literature for randomised controlled trials looking at the effects of medically assisted nutrition in adults receiving palliative care. Randomised controlled trials allocate patients to one of two or more treatment groups in a random manner and provide the most accurate information on the best treatment. The search was conducted in April 2013 and March 2014.</P>
<P>
<B>Key results</B>
</P>
<P>We found no randomised controlled trials. As a result, it is not possible to define the benefits and harms of this treatment clearly.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2014-04-16 12:55:00 +0100" MODIFIED_BY="Anna Hobson">
<ABS_BACKGROUND MODIFIED="2013-12-11 05:22:49 +0000" MODIFIED_BY="[Empty name]">
<P>Many palliative care patients have a reduced oral intake during their illness. The management of this can include the provision of medically assisted nutrition with the aim of prolonging the length of life of a patient, improving their quality of life, or both. This is an updated version of the original Cochrane review published in Issue 4, 2008.<BR/>
</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2008-07-23 11:59:13 +0100" MODIFIED_BY="Laila Tyrrell">
<P>To determine the effect of medically assisted nutrition on the quality and length of life of palliative care patients.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2014-04-16 12:55:00 +0100" MODIFIED_BY="Anna Hobson">
<P>We identified studies from searching Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, CINAHL, CANCERLIT, Caresearch, Dissertation abstracts, SCIENCE CITATION INDEX and the reference lists of all eligible trials, key textbooks and previous systematic reviews. The date of the latest search was 26 March 2014.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2008-08-12 16:20:27 +0100" MODIFIED_BY="Jessica R Thomas">
<P>All relevant randomised controlled trials (RCTs) or prospective controlled trials (if no RCTs were found).</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2014-04-16 12:55:00 +0100" MODIFIED_BY="Anna Hobson">
<P>We found no RCTs or prospectively controlled trials that met the inclusion criteria.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2014-04-16 12:55:00 +0100" MODIFIED_BY="Anna Hobson">
<P>The original review identified four prospective non-controlled trials and the updated search in 2014 identified one more (plus an updated version of a Cochrane review on enteral feeding in motor neuron disease). There were five prospective non-controlled trials (including one qualitative study) that studied medically assisted nutrition in palliative care participants, and one Cochrane systematic review (on motor neuron disease that found no RCTs), but no RCTs or prospective controlled studies.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2014-04-16 12:55:00 +0100" MODIFIED_BY="Anna Hobson">
<P>Since the last version of this review, we found no new studies. There are insufficient good-quality trials to make any recommendations for practice with regards to the use of medically assisted nutrition in palliative care patients.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2014-04-17 11:22:41 +0100" MODIFIED_BY="Anna Hobson">
<BACKGROUND MODIFIED="2014-04-17 11:22:41 +0100" MODIFIED_BY="Anna Hobson">
<P>This review is an update of a previously published review in <I>The Cochrane Library</I> (Issue 2, 2008) on "Medically assisted nutrition for palliative care in adult patients" (<LINK REF="REF-Good-2008" TYPE="REFERENCE">Good 2008</LINK>). Many palliative care patients have a reduced oral intake during their illness. The cause of this varies, but may be part of a physical obstruction, anorexia/cachexia syndrome, generalised weakness, bowel obstruction, loss of desire to eat or no specific cause may be identified. The most common time for this decreased oral intake is during the terminal phase, when the patient becomes less conscious and, therefore, less able to receive nutrition orally (<LINK REF="REF-Morita-1998" TYPE="REFERENCE">Morita 1998</LINK>).</P>
<P>Management of this condition includes discussion with the patient, family and staff involved and either no medical intervention (but continued attention to treating any symptomatic problems, including good mouth care) or the provision of nutrition with medical assistance. The aim of this intervention can be to prolong the length of life of a participant, improve their quality of life (QoL), or both. These benefits may come via the reversal of the physiological factors associated with the patient's decline. Balanced against these potential benefits are adverse events that can be associated with any intervention (infection, bleeding, pain, etc.) (<LINK REF="REF-Bozzetti-1996" TYPE="REFERENCE">Bozzetti 1996</LINK>). It is also essential to assess the psychological and the spiritual impact of undergoing the treatment and what their expectations of medically assisted nutrition are.</P>
<P>Medically assisted nutrition can be performed via a tube inserted into any part of the gastrointestinal system (enteral) or via a tube inserted into the venous system (parenteral). There is some controversy and views vary on the ethics of medically assisted nutrition (<LINK REF="REF-Casarett-2005" TYPE="REFERENCE">Casarett 2005</LINK>). The first ethical controversy centres on whether medically assisted nutrition is a medical intervention or a basic provision of comfort. Second, there is controversy as to how and by whom decisions should be made with regards to medically assisted nutrition in patients who no longer have the capacity to make decisions for themselves. This review will concentrate on assessing the benefit of provision of nutrition with medical assistance versus the harm caused by such intervention in palliative care patients. It is only with this information that clinicians and patients can make informed decisions about whether this type of intervention is beneficial or harmful to an individual patient.</P>
<P>A separate Cochrane review has been conducted considering the provision of medically assisted hydration for palliative care patients (<LINK REF="REF-Good-2014" TYPE="REFERENCE">Good 2014</LINK>).</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2014-04-16 12:55:00 +0100" MODIFIED_BY="Anna Hobson">
<P>To determine the effect of medically assisted nutrition on the QoL and length of life of palliative care patients.</P>
</OBJECTIVES>
<METHODS MODIFIED="2014-04-17 11:09:20 +0100" MODIFIED_BY="Anna Hobson">
<SELECTION_CRITERIA MODIFIED="2014-04-16 12:55:00 +0100" MODIFIED_BY="Anna Hobson">
<CRIT_STUDIES MODIFIED="2008-07-23 11:59:50 +0100" MODIFIED_BY="Laila Tyrrell">
<P>All relevant randomised controlled studies (RCTs) or prospective controlled studies (if no RCTs were found).</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2014-04-16 12:55:00 +0100" MODIFIED_BY="Anna Hobson">
<P>Participants included:<BR/>
</P>
<UL>
<LI>palliative care participants who received medically assisted nutrition;</LI>
<LI>patients receiving palliative care (<LINK REF="REF-WHO-2005" TYPE="REFERENCE">WHO 2005</LINK>);</LI>
<LI>(but not be limited to) incurable cancer, dementia, neurodegenerative diseases (e.g. motor neuron disease), human immunodeficiency virus, chronic airways limitation and chronic heart failure whose prognosis was limited and the focus of care was QoL (<LINK REF="REF-Doyle-2004" TYPE="REFERENCE">Doyle 2004</LINK>);</LI>
<LI>adults aged 18 years and above, both male and female and in any setting such as home, hospice or hospital.</LI>
</UL>
<P>We did not limit included participants to those in the terminal phase of their illness. We excluded participants who were having medically assisted nutrition as part of a perioperative, chemotherapy or radiotherapy regimen, or because of chemotherapy or radiotherapy adverse effects.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2014-04-16 12:55:00 +0100" MODIFIED_BY="Anna Hobson">
<SUBSECTION>
<HEADING LEVEL="4">Medically assisted administration of nutrition</HEADING>
<UL>
<LI>Parenteral nutrition - administration of nutritional liquid via a central or peripheral venous catheter that does not directly enter the gastrointestinal system.</LI>
<LI>Enteral nutrition - administration of nutritional liquid through a tube via the gastrointestinal system (nasogastric tube, jejunostomy, gastrostomy).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparisons</HEADING>
<UL>
<LI>Placebo.</LI>
<LI>No intervention.</LI>
<LI>Usual treatment or supportive care.</LI>
</UL>
</SUBSECTION>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2014-04-16 12:55:00 +0100" MODIFIED_BY="Anna Hobson">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2014-04-16 12:55:00 +0100" MODIFIED_BY="Anna Hobson">
<OL>
<LI>QoL on any measure (including symptom assessment scales).</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2014-04-16 12:55:00 +0100" MODIFIED_BY="Anna Hobson">
<OL>
<LI>Survival.</LI>
<LI>Adverse events.</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2014-04-17 11:09:20 +0100" MODIFIED_BY="Anna Hobson">
<ELECTRONIC_SEARCHES MODIFIED="2014-04-17 11:09:20 +0100" MODIFIED_BY="Anna Hobson">
<P>We searched the following electronic databases using a search strategy developed for MEDLINE, but modified appropriately for each database. The search strategies can be found in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.<BR/>
</P>
<UL>
<LI>Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I>)<I> (</I>Issue 2, 2014, ).</LI>
<LI>MEDLINE (Ovid) 1966 to 25/03/2014.</LI>
<LI>EMBASE (Ovid) 1980 to 25/03/2014.</LI>
<LI>SCIENCE CITATION INDEX (ISI Web of Science) (1900 to March 2014).</LI>
<LI>CINAHL (EBSCO) (1982 to March 2014).</LI>
<LI>CANCERLIT (up to February 2008).</LI>
<LI>Caresearch - database listing conference proceedings and grey literature (up to February 2008).</LI>
<LI>Dissertation abstracts (up to February 2008).</LI>
</UL>
<P>Date of most recent search: March 2014.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2014-04-16 12:55:00 +0100" MODIFIED_BY="Anna Hobson">
<SUBSECTION>
<HEADING LEVEL="3">Reference lists</HEADING>
<P>We searched the reference lists of all eligible trials, key textbooks and previous systematic reviews for additional studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Language</HEADING>
<P>The search attempted to identify all relevant studies irrespective of language. We found no non-English papers.</P>
<P>The subject search used a combination of controlled vocabulary and free-text terms based on the search strategy for searching MEDLINE. Please see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> for the search strategies used for each database. </P>
<P>We adapted this search strategy for other databases searched.</P>
</SUBSECTION>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2014-04-16 12:55:01 +0100" MODIFIED_BY="Anna Hobson">
<STUDY_SELECTION MODIFIED="2014-04-16 12:55:01 +0100" MODIFIED_BY="Anna Hobson">
<P>The original search was performed in July 2008. Subsequent searches were performed in April 2013 and March 2014 for the update of this review.</P>
<P>After review of the title and abstracts, nine references were retrieved in full. None of these studies met the inclusion criteria. However, there was one new prospective non-controlled trial.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2014-04-16 12:55:01 +0100" MODIFIED_BY="Anna Hobson">
<SUBSECTION>
<HEADING LEVEL="3">Data extraction</HEADING>
<P>We planned to obtain the following information for each study:<BR/>
</P>
<UL>
<LI>study methods (study design, allocation, blinding, setting, inclusion criteria);</LI>
<LI>participants (sample size, exclusions/inclusions, number, disease, duration of trial, withdrawals and dropouts, site - e.g. hospital, hospice, home);</LI>
<LI>intervention (type, route of delivery, control used);</LI>
<LI>outcome (QoL, symptom measures, survival, time from death intervention was initiated);</LI>
<LI>adverse effects.</LI>
</UL>
<P>Two review authors planned to extract the data independently.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Quality</HEADING>
<P>We planned to assess the methodological quality of all included trials using two scales. We would have assessed:</P>
<OL>
<LI>RCTs via the Oxford Quality Scale devised by Jadad et al (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>);</LI>
<LI>non-RCTs using a scale devised by Rinck et al (<LINK REF="REF-Rinck-1997" TYPE="REFERENCE">Rinck 1997</LINK>).</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data analysis</HEADING>
<P>We would have assessed the overall effectiveness of medically assisted nutrition in palliative care participants and undertaken a specific subgroup analysis (where possible)by:<BR/>
</P>
<UL>
<LI>study design:</LI>
</UL>
<UL>
<UL>
<LI>data from RCTs and prospective controlled studies were to be evaluated separately;</LI>
</UL>
</UL>
<UL>
<LI>participants:</LI>
</UL>
<UL>
<UL>
<LI>cancer,</LI>
<LI>non-cancer,</LI>
<LI>dementia,</LI>
<LI>neurodegenerative diseases;</LI>
</UL>
</UL>
<UL>
<LI>intervention:</LI>
</UL>
<UL>
<UL>
<LI>medically assisted nutrition - parenteral, enteral nutrition;</LI>
</UL>
</UL>
<UL>
<LI>study quality;</LI>
<LI>timing of intervention (in relation to death);</LI>
<LI>site.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Statistical analysis</HEADING>
<P>We identified no studies that were suitable for evaluation.</P>
</SUBSECTION>
</DATA_EXTRACTION>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2014-04-16 12:55:01 +0100" MODIFIED_BY="Anna Hobson">
<STUDY_DESCRIPTION MODIFIED="2014-04-16 12:55:01 +0100" MODIFIED_BY="Anna Hobson">
<P>No studies met the inclusion criteria. Please see <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> for details of the study selection process.</P>
<EXCLUDED_STUDIES_DESCR MODIFIED="2014-04-16 12:55:01 +0100" MODIFIED_BY="Anna Hobson">
<P>Please see <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> and the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2014-04-16 12:55:01 +0100" MODIFIED_BY="Anna Hobson">
<P>We evaluated no studies for methodological quality.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2014-04-16 12:55:01 +0100" MODIFIED_BY="Anna Hobson">
<P>We identified no RCTs or prospectively controlled trials that met the inclusion criteria.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2014-04-16 12:55:01 +0100" MODIFIED_BY="Anna Hobson">
<P>The objective of this systematic review was to determine the effectiveness of medically assisted nutrition in palliative care patients (of all ages) on their QoL and length of life. Extensive searching of the literature produced no RCTs or prospective controlled trials that fulfilled the inclusion criteria. The discussion will focus only on prospective trials that were retrieved, as this represents the next highest study quality design. However, the studies are all of a low quality because of their design, and therefore caution is needed in interpreting any of the results.</P>
<P>This updated search identified five prospective non-controlled trials (including one qualitative study) that studied medically assisted nutrition in palliative care participants (<LINK REF="STD-Bozzetti-2002" TYPE="STUDY">Bozzetti 2002</LINK>; <LINK REF="STD-Chermesh-2011" TYPE="STUDY">Chermesh 2011</LINK>; <LINK REF="STD-Meier-2001" TYPE="STUDY">Meier 2001</LINK>; <LINK REF="STD-Orrevall-2005" TYPE="STUDY">Orrevall 2005</LINK>; <LINK REF="STD-Pironi-1997" TYPE="STUDY">Pironi 1997</LINK>), and one updated Cochrane systematic review (<LINK REF="STD-Katzberg-2011" TYPE="STUDY">Katzberg 2011</LINK>). One study included participants with advanced dementia (<LINK REF="STD-Meier-2001" TYPE="STUDY">Meier 2001</LINK>). The other four studies included only participants with advanced cancer (<LINK REF="STD-Bozzetti-2002" TYPE="STUDY">Bozzetti 2002</LINK>; <LINK REF="STD-Chermesh-2011" TYPE="STUDY">Chermesh 2011</LINK>; <LINK REF="STD-Orrevall-2005" TYPE="STUDY">Orrevall 2005</LINK>; <LINK REF="STD-Pironi-1997" TYPE="STUDY">Pironi 1997</LINK>). In three studies, participants received only parenteral nutrition (<LINK REF="STD-Bozzetti-2002" TYPE="STUDY">Bozzetti 2002</LINK>; <LINK REF="STD-Chermesh-2011" TYPE="STUDY">Chermesh 2011</LINK>; <LINK REF="STD-Orrevall-2005" TYPE="STUDY">Orrevall 2005</LINK>), while in another two studies, the included participants had enteral nutrition (<LINK REF="STD-Katzberg-2011" TYPE="STUDY">Katzberg 2011</LINK>; <LINK REF="STD-Meier-2001" TYPE="STUDY">Meier 2001</LINK>). In one study, included participants received either enteral or parenteral nutrition (<LINK REF="STD-Pironi-1997" TYPE="STUDY">Pironi 1997</LINK>). The Cochrane review assessed participants with motor neuron disease, but found no RCTs (<LINK REF="STD-Katzberg-2011" TYPE="STUDY">Katzberg 2011</LINK>).</P>
<P>Survival was measured in four studies (<LINK REF="STD-Bozzetti-2002" TYPE="STUDY">Bozzetti 2002</LINK>; <LINK REF="STD-Chermesh-2011" TYPE="STUDY">Chermesh 2011</LINK>; <LINK REF="STD-Meier-2001" TYPE="STUDY">Meier 2001</LINK>; <LINK REF="STD-Pironi-1997" TYPE="STUDY">Pironi 1997</LINK>), and evaluated in the systematic review (<LINK REF="STD-Katzberg-2011" TYPE="STUDY">Katzberg 2011</LINK>). QoL was used as an outcome measure in three of the studies (<LINK REF="STD-Bozzetti-2002" TYPE="STUDY">Bozzetti 2002</LINK>; <LINK REF="STD-Katzberg-2011" TYPE="STUDY">Katzberg 2011</LINK>; <LINK REF="STD-Orrevall-2005" TYPE="STUDY">Orrevall 2005</LINK>). Two studies determined the effect of the intervention on the Karnofsky Performance Scale (KPS) (<LINK REF="STD-Bozzetti-2002" TYPE="STUDY">Bozzetti 2002</LINK>; <LINK REF="STD-Pironi-1997" TYPE="STUDY">Pironi 1997</LINK>). Two studies recorded adverse events of the interventions (<LINK REF="STD-Chermesh-2011" TYPE="STUDY">Chermesh 2011</LINK>; <LINK REF="STD-Pironi-1997" TYPE="STUDY">Pironi 1997</LINK>). The qualitative study analysed the positive and negative features according to the themes derived from the data (<LINK REF="STD-Orrevall-2005" TYPE="STUDY">Orrevall 2005</LINK>).</P>
<P>In one prospective, cohort study of participants with advanced dementia, there was no significant difference in survival between participants with percutaneous endoscopic gastrostomy (PEG) inserted (median 195 days, range 21 to 1405 days), and participants without PEG insertion (median 189 days, range four to 1502) (P value = 0.9) (<LINK REF="STD-Meier-2001" TYPE="STUDY">Meier 2001</LINK>). The Cochrane review had conflicting results, in that four studies (two prospective and two retrospective) found a longer survival in participants who had a PEG, while the other seven studies (one prospective and six retrospective) found no difference (<LINK REF="STD-Katzberg-2011" TYPE="STUDY">Katzberg 2011</LINK>). <LINK REF="STD-Bozzetti-2002" TYPE="STUDY">Bozzetti 2002</LINK> found that participants on home parenteral nutrition (HPN) had a median survival of four months (range one to 14), while <LINK REF="STD-Chermesh-2011" TYPE="STUDY">Chermesh 2011</LINK> found the median survival for patients on HPN was 140 days (range 20 to 783). There was a significant difference in survival between participants with a better performance status (KPS &gt; 50; median survival 211 days) compared with participants with a worse performance status (KPS &lt; 50; median survival 62 days). The mean survival was used when <LINK REF="STD-Pironi-1997" TYPE="STUDY">Pironi 1997</LINK> considered participants on HPN (12.2 weeks) and participants on home enteral nutrition (HEN) (17.2 weeks). QoL did not improve after PEG insertion for participants with motor neuron disease (<LINK REF="STD-Katzberg-2011" TYPE="STUDY">Katzberg 2011</LINK>), or at one month in people with advanced cancer (<LINK REF="STD-Bozzetti-2002" TYPE="STUDY">Bozzetti 2002</LINK>). There was a perceived benefit in QoL in the qualitative study (<LINK REF="STD-Orrevall-2005" TYPE="STUDY">Orrevall 2005</LINK>). In one study, the KPS was stable until a progressive decline at three months prior to death (<LINK REF="STD-Bozzetti-2002" TYPE="STUDY">Bozzetti 2002</LINK>), while another study found that at one month after intervention the KPS was increased in 13 participants, decreased in 19 participants, and unchanged in 132 participants (<LINK REF="STD-Pironi-1997" TYPE="STUDY">Pironi 1997</LINK>). The qualitative study of people with advanced cancer in Sweden found that HPN produced positive features including assurance that nutrition was being met, and this led to a perceived benefit on energy, strength and activity (<LINK REF="STD-Orrevall-2005" TYPE="STUDY">Orrevall 2005</LINK>). It was also seen as decreasing the feeling of "pressure to eat" and more acceptance of whatever was able to be eaten orally.</P>
<P>
<LINK REF="STD-Pironi-1997" TYPE="STUDY">Pironi 1997</LINK> found that with HEN, there was nasogastric tube blockage/dislodgment in 0.26 per year of HEN and PEG site infection in one participant and hub replacement in two participants, while the complications of treatment with HPN (per year of treatment) were catheter sepsis (0.67), deep vein thrombosis (DVT) (0.16) and metabolic instability (0.50). This study also attempted to assess the burden of medically assisted nutrition for participants and their families. However, this was only done as a judgement by nutrition staff, and was therefore open to a large element of bias. They found that medically assisted nutrition was well accepted in 124 cases (19 HPN), with annoyance in 30 cases (seven HPN) and scarcely tolerated in 10 cases (three HPN). In the study by <LINK REF="STD-Chermesh-2011" TYPE="STUDY">Chermesh 2011</LINK>, eight out the 28 patients (29%) had total parenteral nutrition (TPN)-related complications. Six patients had line sepsis, one patient had bone pain (likely to be from the TPN solution) and one patient had hyperkalaemia. The qualitative study found that the negative features of HPN were related to physical symptoms of nausea, vomiting, drowsiness and headache, as well as HPN placing a restriction on their family life and social involvement (<LINK REF="STD-Orrevall-2005" TYPE="STUDY">Orrevall 2005</LINK>).</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2014-04-16 12:55:01 +0100" MODIFIED_BY="Anna Hobson">
<IMPLICATIONS_PRACTICE MODIFIED="2014-04-16 12:55:01 +0100" MODIFIED_BY="Anna Hobson">
<P>Since the last version of this review, we found no new studies. There are insufficient good-quality studies to make any recommendations for practice with regards to the use of medically assisted nutrition in palliative care patients. Clinicians will need to make a decision based on the perceived benefits and harms of medically assisted nutrition in individual patient circumstances, without the benefit of high-quality evidence to guide them. The uncontrolled prospective studies described would suggest that patients with a good performance status and medium- to long-term prognosis (months to years) may benefit from medically assisted nutrition. However, the evidence base to support this at the moment is weak and any intention to use this treatment should be monitored carefully and ideally fed in to further research.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2014-04-16 12:55:01 +0100" MODIFIED_BY="Anna Hobson">
<SUBSECTION>
<HEADING LEVEL="3">Trial design</HEADING>
<P>There are very few quality studies that have examined medically assisted nutrition in palliative care patients. It may be difficult to perform an RCT in this area. The logistics of recruiting participants to any palliative care trial are well known (<LINK REF="REF-Rinck-1997" TYPE="REFERENCE">Rinck 1997</LINK>), but are especially so with regards to medically assisted nutrition. Further trials of the effect of medically assisted nutrition would be useful in two distinct palliative care populations. The first is patients who develop the anorexia/cachexia syndrome. The second is in patients who are unable to swallow, but whose prognosis (from their cancer/illness, e.g. motor neuron disease) would seem to be longer than their prognosis from the aphagia. The difficulty in this situation is the reliance on the physician's ability to provide a prognosis, and this is not always accurate (<LINK REF="REF-Glare-2003" TYPE="REFERENCE">Glare 2003</LINK>).</P>
<P>As well as looking at the possibility of RCTs in this area, the evidence base will be improved with at least some prospective controlled trials, and even with more prospective uncontrolled trials. This may need innovative designs such as comparisons between different centres that have different nutrition practices or by following up cohorts of participants who are offered medically assisted nutrition, in whom some proceed and some do not (as long as the two groups are similar).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Patient groups</HEADING>
<P>The studies in this review did not have well-defined patient populations. Palliative care is performed in hospital, inpatient palliative care units and the community. Trials need to be performed in all these areas to allow external validity (able to be applied to a similar patients as those seen in a trial) to different palliative care populations. It would also be helpful to define at what stage of their illness participants are being given medically assisted nutrition. The reasons and aims of nutrition in the last few days/weeks of life may be very different to those of participants with a longer prognosis. The prospective prediction of prognosis is difficult, and it may be better to stratify participants according to performance status.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Interventions</HEADING>
<P>Medically administered nutrition can be given by many different routes. Further trials are needed to determine the optimum route and dose.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Outcomes</HEADING>
<P>It is important that clinically relevant outcomes are clearly defined and are the most clinically useful to this situation. In this patient population, this includes energy levels, functional status and overall quality of life. As well as these, the effect of this intervention on overall survival needs to be reported. It is also important that the adverse events are well defined so that the risk of treatment can be balanced against any benefits.</P>
</SUBSECTION>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2014-04-16 13:02:55 +0100" MODIFIED_BY="Anna Hobson">
<P>John Cavenagh, Mark Mather and Peter Ravenscroft were authors on the original review but did not contribute to this update.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2014-04-16 12:55:01 +0100" MODIFIED_BY="Anna Hobson">
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2014-04-16 12:55:01 +0100" MODIFIED_BY="Anna Hobson">
<P>Phillip Good: formulated question, wrote protocol, searched for studies, reviewed titles and abstracts, retrieved articles, assessed article quality, wrote review, wrote update.</P>
<P>Russell Richard: reviewed titles and abstracts, assessed article quality, performed critical revision of review.</P>
<P>William Syrmis: reviewed titles and abstracts, assessed article quality, performed critical revision of review.</P>
<P>Sue Jenkins-Marsh: reviewed titles and abstracts, assessed article quality, performed critical revision of review.</P>
<P>Jane Stephens: reviewed titles and abstracts, assessed article quality, performed critical revision of review.<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2014-04-17 11:23:41 +0100" MODIFIED_BY="Anna Hobson">
<P>For the 2014 update, the title was amended slightly from 'Medically assisted nutrition for palliative care in adult patients' to match the format of the authors' second review, 'Medically assisted hydration for adult palliative care patients' (<LINK REF="REF-Good-2014" TYPE="REFERENCE">Good 2014</LINK>), which was updated simultaneously.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2014-04-17 11:22:41 +0100" MODIFIED_BY="Anna Hobson">
<STUDIES MODIFIED="2014-04-02 09:27:46 +0100" MODIFIED_BY="Anne Lawson">
<INCLUDED_STUDIES/>
<EXCLUDED_STUDIES MODIFIED="2014-04-02 09:27:46 +0100" MODIFIED_BY="Anne Lawson">
<STUDY DATA_SOURCE="PUB" ID="STD-Bozzetti-2002" NAME="Bozzetti 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;Journal Article. et al: Gilli G, Percolla S, Pironi L. Quality of life and length of survival in advanced cancer patients on home parenteral nutrition. 0261-5614 (Print)&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bozzetti F, Cozzaglio L, Biganzoli E, Chiavenna G, De Cicco M, Donati D, et al</AU>
<TI>Quality of life and length of survival in advanced cancer patients on home parenteral nutrition</TI>
<SO>Clinical Nutrition</SO>
<YR>2002</YR>
<VL>21</VL>
<NO>4</NO>
<PG>281-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chermesh-2011" MODIFIED="2014-04-02 09:27:31 +0100" MODIFIED_BY="Anne Lawson" NAME="Chermesh 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-04-02 09:27:31 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Chermesh I, Mashiach T, Amit A, Haim N, Papier I, Efergan R, et al</AU>
<TI>Home parenteral nutrition (HTPN) for incurable patients with cancer with gastrointestinal obstruction: do the benefits outweigh the risks?</TI>
<SO>Medical Oncology</SO>
<YR>2011</YR>
<VL>28</VL>
<NO>1</NO>
<PG>83-8</PG>
<IDENTIFIERS MODIFIED="2013-12-13 06:04:15 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-13 06:06:49 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Katzberg-2011" MODIFIED="2014-03-21 09:57:49 +0000" MODIFIED_BY="[Empty name]" NAME="Katzberg 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-03-21 09:57:49 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="COCHRANE_REVIEW">
<AU>Katzberg HD, Benatar M</AU>
<TI>Enteral tube feeding for amyotrophic lateral sclerosis/motor neuron disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>1</NO>
<PG>CD004030</PG>
<PB>Wiley-Blackwell</PB>
<IDENTIFIERS MODIFIED="2014-03-21 04:54:25 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-03-21 04:54:14 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004030.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meier-2001" MODIFIED="2014-04-02 09:27:46 +0100" MODIFIED_BY="Anne Lawson" NAME="Meier 2001" YEAR="2001">
<REFERENCE MODIFIED="2014-04-02 09:27:46 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meier DE, Ahronheim JC, Morris J, Baskin-Lyons S, Morrison RS</AU>
<TI>High short-term mortality in hospitalized patients with advanced dementia: lack of benefit of tube feeding</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2001</YR>
<VL>161</VL>
<NO>4</NO>
<PG>594-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="0003-9926"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Orrevall-2005" NAME="Orrevall 2005" YEAR="2005">
<REFERENCE NOTES="&lt;p&gt;Journal Article. 0261-5614 (Print)&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Orrevall Y, Tishelman C, Permert J</AU>
<TI>Home parenteral nutrition: a qualitative interview study of the experiences of advanced cancer patients and their families</TI>
<SO>Clinical Nutrition</SO>
<YR>2005</YR>
<VL>24</VL>
<NO>6</NO>
<PG>961-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pironi-1997" NAME="Pironi 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Pironi L&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pironi L, Ruggeri E, Tanneberger S, Giordani S, Pannuti F, Miglioli M</AU>
<TI>Home artificial nutrition in advanced cancer</TI>
<SO>Journal of the Royal Society of Medicine</SO>
<YR>1997</YR>
<VL>90</VL>
<NO>11</NO>
<PG>597-603</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2014-04-17 11:22:41 +0100" MODIFIED_BY="Anna Hobson">
<ADDITIONAL_REFERENCES MODIFIED="2014-04-17 11:22:24 +0100" MODIFIED_BY="Anna Hobson">
<REFERENCE ID="REF-Bozzetti-1996" MODIFIED="2008-07-23 12:05:04 +0100" MODIFIED_BY="Laila Tyrrell" NAME="Bozzetti 1996" TYPE="JOURNAL_ARTICLE">
<AU>Bozzetti F, Amadori D, Bruera E, Cozzaglio L, Corli O, Filiberti A, et al</AU>
<TI>Guidelines on artificial nutrition versus hydration in terminal cancer patients. European Association for Palliative Care</TI>
<SO>Nutrition</SO>
<YR>1996</YR>
<VL>12</VL>
<NO>3</NO>
<PG>163-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Casarett-2005" MODIFIED="2008-07-23 12:05:08 +0100" MODIFIED_BY="Laila Tyrrell" NAME="Casarett 2005" TYPE="JOURNAL_ARTICLE">
<AU>Casarett D, Kapo J, Caplan A</AU>
<TI>Appropriate use of artificial nutrition and hydration - fundamental principles and recommendations</TI>
<SO>New England Journal of Medicine</SO>
<YR>2005</YR>
<VL>353</VL>
<NO>24</NO>
<PG>2607-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Doyle-2004" NAME="Doyle 2004" TYPE="BOOK">
<AU>Doyle D, Hanks G, Cherny NI, Calman K</AU>
<SO>Oxford Textbook of Palliative Medicine</SO>
<YR>2004</YR>
<EN>3rd</EN>
<PB>Oxford University Press</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Glare-2003" MODIFIED="2008-07-23 12:05:12 +0100" MODIFIED_BY="Laila Tyrrell" NAME="Glare 2003" TYPE="JOURNAL_ARTICLE">
<AU>Glare P, Virik K, Jones M, Hudson M, Eychmuller S, Simes J, et al</AU>
<TI>A systematic review of physicians' survival predictions in terminally ill cancer patients</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7408</NO>
<PG>195-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="1468-5833 (Electronic)"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Good-2014" MODIFIED="2014-04-17 11:22:24 +0100" MODIFIED_BY="Anna Hobson" NAME="Good 2014" TYPE="COCHRANE_REVIEW">
<AU>Good P, Cavenagh J, Mather M, Ravenscroft P</AU>
<TI>Medically assisted hydration for adult palliative care patients</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2014</YR>
<NO>4</NO>
<PB>Wiley-Blackwell</PB>
<CY>Chichester</CY>
<IDENTIFIERS MODIFIED="2014-04-17 11:22:24 +0100" MODIFIED_BY="Anna Hobson">
<IDENTIFIER MODIFIED="2014-04-17 11:22:24 +0100" MODIFIED_BY="Anna Hobson" TYPE="DOI" VALUE="10.1002/14651858.CD006273.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" MODIFIED="2014-04-02 09:28:39 +0100" MODIFIED_BY="Anne Lawson" NAME="Jadad 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al</AU>
<TI>Assessing the quality of reports of randomized clinical trials: is blinding necessary?</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<NO>1</NO>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Morita-1998" MODIFIED="2008-07-23 12:05:29 +0100" MODIFIED_BY="Laila Tyrrell" NAME="Morita 1998" TYPE="JOURNAL_ARTICLE">
<AU>Morita T, Ichiki T, Tsunoda J, Inoue S, Chihara S</AU>
<TI>A prospective study on the dying process in terminally ill cancer patients</TI>
<SO>American Journal of Hospital Palliative Care</SO>
<YR>1998</YR>
<VL>15</VL>
<NO>4</NO>
<PG>217-22</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="1049-9091 (Print)"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rinck-1997" MODIFIED="2008-07-23 12:05:32 +0100" MODIFIED_BY="Laila Tyrrell" NAME="Rinck 1997" TYPE="JOURNAL_ARTICLE">
<AU>Rinck GC, van den Bos GA, Kleijnen J, de Haes HJ, Schade E, Veenhof CH</AU>
<TI>Methodologic issues in effectiveness research on palliative cancer care: a systematic review</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1997</YR>
<VL>15</VL>
<NO>4</NO>
<PG>1697-707</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2005" MODIFIED="2014-04-02 09:54:08 +0100" MODIFIED_BY="Anne Lawson" NAME="WHO 2005" TYPE="OTHER">
<AU>World Health Organization</AU>
<TI>WHO Definition of Palliative Care</TI>
<SO>www.who.int/cancer/palliative/definition/en/</SO>
<YR>(accessed 2 April 2014)</YR>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2014-04-17 11:22:41 +0100" MODIFIED_BY="Anna Hobson">
<REFERENCE ID="REF-Good-2008" MODIFIED="2014-04-17 11:22:41 +0100" MODIFIED_BY="Anna Hobson" NAME="Good 2008" TYPE="COCHRANE_REVIEW">
<AU>Good P, Cavenagh J, Mather M, Ravenscroft P</AU>
<TI>Medically assisted nutrition for palliative care in adult patients</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2013-12-13 06:51:25 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-13 06:51:25 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006273.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2014-04-16 12:55:01 +0100" MODIFIED_BY="Anna Hobson">
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2014-04-16 12:55:01 +0100" MODIFIED_BY="Anna Hobson" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2014-04-16 12:55:01 +0100" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Bozzetti-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-16 12:55:01 +0100" MODIFIED_BY="Anna Hobson">
<P>Prospective non-controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-13 06:02:40 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chermesh-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-13 06:02:40 +0000" MODIFIED_BY="[Empty name]">
<P>Prospective non-controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-16 12:55:01 +0100" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Katzberg-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-16 12:55:01 +0100" MODIFIED_BY="Anna Hobson">
<P>Cochrane systematic review - no RCTs, retrospective case control studies, and prospective cohort studies</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-16 12:55:01 +0100" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Meier-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-16 12:55:01 +0100" MODIFIED_BY="Anna Hobson">
<P>Prospective non-controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-16 12:55:01 +0100" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Orrevall-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-16 12:55:01 +0100" MODIFIED_BY="Anna Hobson">
<P>Prospective non-controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-16 12:55:01 +0100" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Pironi-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-16 12:55:01 +0100" MODIFIED_BY="Anna Hobson">
<P>Prospective non-controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2014-04-16 12:55:12 +0100" MODIFIED_BY="Anna Hobson">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2014-04-16 12:55:12 +0100" MODIFIED_BY="Anna Hobson" NO="1">
<TITLE>Data on excluded studies</TITLE>
<TABLE COLS="6" ROWS="7">
<TR>
<TH VALIGN="TOP">
<P>Study ID</P>
</TH>
<TH VALIGN="TOP">
<P>Methods</P>
</TH>
<TH VALIGN="TOP">
<P>Participants</P>
</TH>
<TH VALIGN="TOP">
<P>Interventions</P>
</TH>
<TH VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH VALIGN="TOP">
<P>Notes</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Bozzetti-2002" TYPE="STUDY">Bozzetti 2002</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Prospective, observational study</P>
</TD>
<TD VALIGN="TOP">
<P>69 adults with cancer<BR/>6 centres in Italy<BR/>Indications for HPN were intestinal obstruction (n = 58), malnutrition (n = 7), not specified (n = 4)</P>
</TD>
<TD VALIGN="TOP">
<P>HPN<BR/>External tunnelled catheters (n = 51) and porta cath (n = 18)</P>
</TD>
<TD VALIGN="TOP">
<P>Median survival was 4 months, after participants began HPN.<BR/>At 1 month, there was no significant change from baseline with regards to QoL (using Rotterdam Symptom Checklist) with 40% improved, 50% deteriorated and 10% no change. The KPS was stable until progressive decline at 3 months prior to death</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Chermesh-2011" TYPE="STUDY">Chermesh 2011</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Prospective, observational study</P>
</TD>
<TD VALIGN="TOP">
<P>28 patients with incurable cancer and gastrointestinal obstruction, treated at a tertiary hospital in Israel, referred to a multidisciplinary committee to consider HPN therapy</P>
</TD>
<TD VALIGN="TOP">
<P>HPN therapy</P>
</TD>
<TD VALIGN="TOP">
<P>Median survival was 140 days (range 20-783)</P>
<P>Survival varied according to KPS:</P>
<P>KPS &gt; 50 median survival 211 (range 50-783)</P>
<P>KPS &lt; 50 median survival 62 (range 20-141), P value &lt; 0.01</P>
<P>Complications: sepsis (n = 6), bone pain (n = 1), hyperkalaemia (n = 1)</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Katzberg-2011" TYPE="STUDY">Katzberg 2011</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Cochrane systematic review</P>
</TD>
<TD VALIGN="TOP">
<P>Motor neuron disease</P>
</TD>
<TD VALIGN="TOP">
<P>Medically assisted nutrition (via enteral tube feeding)</P>
</TD>
<TD VALIGN="TOP">
<P>There were no RCTs found. The review discussed 11 studies. There were 3 prospective studies and 8 retrospective studies. All 11 studies tested for survival advantage of intervention. 4 found a longer survival in participants who had a PEG, while the other 7 found no difference. Only 3 studies examined nutritional outcomes and these suggested a positive advantage for those participants with PEGs. Only 2 studies considered QoL, and both showed no improvement in QoL after PEG insertion</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Meier-2001" TYPE="STUDY">Meier 2001</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Prospective, cohort study.<BR/>This was part of a study considering increased consultation versus usual care in the management of participants with advanced dementia</P>
</TD>
<TD VALIGN="TOP">
<P>182 eligible participants - 99 consented to inclusion in study<BR/>The 93 participants were excluded because of:<BR/>- no available surrogate decision maker (n = 40),<BR/>- surrogate decision maker unable to understand and participate in informed consent (n = 19),<BR/>- surrogate decision maker refused informed consent (n = 5),<BR/>- subject imminently dying or medically unstable (n = 8),<BR/>- language barrier (n = 3),</P>
<P>- family conflict (n = 3) and</P>
<P>- transferred/discharged/died (n = 5)<BR/>
<BR/>The participants had been admitted to a New York hospital with an acute illness (pneumonia or urinary tract infection (n = 61), dehydration or metabolic abnormality (n = 12), other (n = 26))<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>Of the 99 study participants, 82 had no feeding tube on admission (2 admitted for insertion of feeding tube). Of these 82 participants, 51 had a PEG inserted during the index admission</P>
</TD>
<TD VALIGN="TOP">
<P>The median survival was not significantly different between those participants with PEG inserted (median 195 days, range 21 to 1405), and participants without PEG insertion (median 189 days, range 4 to 1502) (P value = 0.9)</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Orrevall-2005" TYPE="STUDY">Orrevall 2005</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Qualitative study</P>
</TD>
<TD VALIGN="TOP">
<P>13 participants were interviewed and 11 family members, during 2000 to 2001, in Sweden. These were recruited via AHCT nurses who were asked to contact participants with advanced cancer. Participants contacted were asked to provide names of relatives who were also willing to participate</P>
</TD>
<TD VALIGN="TOP">
<P>9 participants received partial HPN and oral intake, 2 received total HPN and 2 were actually weaned from HPN. The intervention consisted of HPN for at least 2 weeks (and at least 3 times per week), with an AHCT nurse connecting and disconnecting the infusion each time. 10 of the participants died within 6 months of the interview, but 11 lived more than 3 months</P>
</TD>
<TD VALIGN="TOP">
<P>The positive features (according to participants and relatives) included assurance that nutrition was being met, and this led to a perceived benefit on QoL, energy, strength and activity. It was also seen as decreasing the feeling of "pressure to eat" and more acceptance of whatever could be eaten orally. The benefits of HPN were very much related to the close involvement and frequent visits of the AHCT nurses<BR/>The negative features of HPN were related to physical symptoms of nausea, vomiting, drowsiness and headache. As well HPN placed a restriction on the family life and social involvement</P>
</TD>
<TD VALIGN="TOP">
<P>The selection protocol used lends itself to be a large source of bias</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Pironi-1997" TYPE="STUDY">Pironi 1997</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Prospective survey</P>
</TD>
<TD VALIGN="TOP">
<P>Italian advanced cancer patients.<BR/>Participants were described as having advanced cancer when receiving only palliative care</P>
<P>
<BR/>Participants were included if they had hypophagia (oral calorie intake absent or &lt; 50% of basal energy expenditure (Harris-Benedict formula), life expectancy &gt; 6 weeks, suitable participant and family circumstances (controlled or absent pain, no severe vital organ failure, emotional stability, willingness and ability to cope with HAN-related activities and suitable hygienic conditions), and able to give verbal consent<BR/>
<BR/>6838 participants on a hospital-at-home programme - 587 of these referred for assessment of HAN</P>
<P>
<BR/>Of the 587, 164 were eligible and received HAN - 135 HEN, 29 HPN</P>
<P>
<BR/>The reasons for exclusion of the 423 participants included absence of hypophagia (n = 264), estimated life expectancy &lt; 6 weeks, lack of suitable home/family conditions (n = 30) and lack of consent (n = 21)</P>
<P>
<BR/>50 participants (30%) aware of their diagnosis<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>The method of intervention for 135 participants with HEN was using an NG tube (50%), PEG (18%), jejunostomy (27%) and surgical gastrostomy (5%). The infusion method was pump (83%) and via gravity (17%).<BR/>In the 29 participants with HPN, the methods used were non-tunnelled percutaneous catheters (79%), tunnelled percutaneous catheters (14%) and totally implanted ports (7%)</P>
</TD>
<TD VALIGN="TOP">
<P>Mean survival was 17.2 weeks for participants on HEN and 12.2 weeks for participants on HPN. This included 47 participants (29%) who survived less than 6 weeks. This was most common in groups with the primary tumour outside the gastrointestinal tract and head-neck region, and in the group with a KPS &#8804; 40. During the first month of HAN the KPS increased in 13 participants, decreased in 19 participants and was unchanged in 132 participants. 12 participants on HEN became able to go out and look after themselves unaided, while 2 became housebound. Body weight increased in 43 participants, decreased in 21 participants and there was no change in 80 participants - with 20 participants confined to bed and unable to be weighed. Of the 108 participants excluded because their estimated survival was &lt; 6 weeks, 31 (29%) lived &#8805; 6 weeks. During treatment, there were 95 participants (61%) who underwent 155 hospital re-admissions. This included 3 admissions for HPN complications and 7 for jejunostomy positioning<BR/>
<BR/>An attempt was made to record the burden to the participant and families. This was judged by the nutrition staff, and was dependent on the level of complaints of the participant and families. They found that HAN was well accepted in 124 cases (19 HPN), with annoyance in 30 cases (7 HPN), and scarcely tolerated in 10 cases (3 HPN)<BR/>
<BR/>In terms of complications with HEN, there was NG tube blockage/dislodgment in 0.26 per year of HEN and PEG site infection in 1 participant and hub replacement in 2 participants. The complications of treatment with HPN (per year of treatment) were catheter sepsis (0.67), DVT (0.16) and metabolic instability (0.50)<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>AHCT: advanced home care team; DVT: deep vein thrombosis; HAN: home artificial nutrition; HEN: home enteral nutrition; HPN: home parenteral nutrition; KPS: Karnofsky Performance Status; NG: nasogastric; PEG: percutaneous endoscopic gastrostomy; QoL: quality of life; RCT: randomised controlled trial.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES"/>
<FIGURES MODIFIED="2014-04-17 11:08:58 +0100" MODIFIED_BY="Anna Hobson">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2014-04-17 11:08:58 +0100" MODIFIED_BY="Anna Hobson" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAoIAAANhCAYAAABzV9qNAABy00lEQVR42uy9D0Rf/f///2Yuk5m5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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2014-04-16 12:55:44 +0100" MODIFIED_BY="Anna Hobson">
<APPENDIX ID="APP-01" MODIFIED="2014-04-16 12:55:44 +0100" MODIFIED_BY="Anna Hobson" NO="1">
<TITLE MODIFIED="2013-12-18 14:01:57 +0000" MODIFIED_BY="Laila Tyrrell">Search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2014-04-16 12:55:44 +0100" MODIFIED_BY="Anna Hobson">
<P>
<B>Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I>)</B>
</P>
<P>#1 MeSH descriptor: [Palliative Care] explode all trees</P>
<P>#2 palliat*:it,ab,kw (Word variations have been searched)</P>
<P>#3 MeSH descriptor: [Terminally Ill] this term only</P>
<P>#4 MeSH descriptor: [Terminal Care] explode all trees</P>
<P>#5 (terminal* near/6 care*):it,ab,kw (Word variations have been searched)</P>
<P>#6 ((terminal* near/6 ill*) or terminal-stage* or dying or (close near/6 death)):it,ab,kw (Word variations have been searched)</P>
<P>#7 (terminal* near/6 disease*):it,ab,kw (Word variations have been searched)</P>
<P>#8 (end near/3 life):it,ab,kw (Word variations have been searched)</P>
<P>#9 hospice*:it,ab,kw (Word variations have been searched)</P>
<P>#10 ("end-stage disease*" or "end stage disease* or end-stage illness" or "end stage"):it,ab,kw (Word variations have been searched)</P>
<P>#11 "advanced disease*":it,ab,kw (Word variations have been searched)</P>
<P>#12 ("incurable illness*" or "incurable disease*"):it,ab,kw (Word variations have been searched)</P>
<P>#13 ("advanced directive*" or "living will*" or "do-not-resuscitate order*"):it,ab,kw (Word variations have been searched)</P>
<P>#14 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13</P>
<P>#15 MeSH descriptor: [Nutrition Assessment] explode all trees</P>
<P>#16 MeSH descriptor: [Nutrition Therapy] explode all trees</P>
<P>#17 MeSH descriptor: [Feeding Methods] explode all trees</P>
<P>#18 (feed or feeding or fed* or food*):it,ab,kw (Word variations have been searched)</P>
<P>#19 MeSH descriptor: [Food] explode all trees</P>
<P>#20 (diet or nutrition):it,ab,kw (Word variations have been searched)</P>
<P>#21 #15 or #16 or #17 or #18 or #19 or #20</P>
<P>#22 #14 and #21</P>
<P>
<B>MEDLINE (Ovid)</B>
</P>
<P>1 exp Palliative Care/</P>
<P>2 palliat*.tw.</P>
<P>3 Terminally Ill/</P>
<P>4 Terminal Care/</P>
<P>5 (terminal* adj6 care*).tw.</P>
<P>6 ((terminal* adj6 ill*) or terminal-stage* or dying or (close adj6 death)).tw.</P>
<P>7 (terminal* adj6 disease*).tw.</P>
<P>8 (end adj6 life).tw.</P>
<P>9 hospice*.tw.</P>
<P>10 ("end-stage disease*" or "end stage disease* or end-stage illness" or "end stage").tw.</P>
<P>11 "advanced disease*".tw.</P>
<P>12 ("incurable illness*" or "incurable disease*").tw.</P>
<P>13 ("advanced directive*" or "living will*" or "do-not-resuscitate order* ").tw.</P>
<P>14 or/1-13</P>
<P>15 exp nutrition assessment/</P>
<P>16 exp Nutrition Therapy/</P>
<P>17 exp Feeding Methods/</P>
<P>18 (feed or feeding or fed* or food*).tw.</P>
<P>19 exp Food/</P>
<P>20 (diet or nutrition).tw.</P>
<P>21 or/15-20</P>
<P>22 14 and 21</P>
<P>23 (2008* or 2009* or 2010* or 2011* or 2012* or 2013* or 2014*).ed.</P>
<P>24 22 and 23</P>
<P>
<B>EMBASE (Ovid)</B>
</P>
<P>1 exp Palliative Care/</P>
<P>2 palliat*.tw.</P>
<P>3 Terminally Ill/</P>
<P>4 Terminal Care/</P>
<P>5 (terminal* adj6 care*).tw.</P>
<P>6 ((terminal* adj6 ill*) or terminal-stage* or dying or (close adj6 death)).tw.</P>
<P>7 (terminal* adj6 disease*).tw.</P>
<P>8 (end adj6 life).tw.</P>
<P>9 hospice*.tw.</P>
<P>10 ("end-stage disease*" or "end stage disease* or end-stage illness" or "end stage").tw.</P>
<P>11 "advanced disease*".tw.</P>
<P>12 ("incurable illness*" or "incurable disease*").tw.</P>
<P>13 ("advanced directive*" or "living will*" or "do-not-resuscitate order* ").tw.</P>
<P>14 or/1-13</P>
<P>15 exp nutrition assessment/</P>
<P>16 exp Nutrition Therapy/</P>
<P>17 exp Feeding Methods/</P>
<P>18 (feed or feeding or fed* or food*).tw.</P>
<P>19 exp Food/</P>
<P>20 (diet or nutrition).tw.</P>
<P>21 or/15-20</P>
<P>22 14 and 21</P>
<P>23 (2008* or 2009* or 2010* or 2011* or 2012* or 2013* or 2014*).dd.</P>
<P>24 22 and 23</P>
<P>
<B>Web of Science (ISI) - Science Citation Index</B>
</P>
<P># 15 1,620 #14 AND #11</P>
<P># 14 340,224 #13 OR #12</P>
<P># 13 119,763 Topic=((diet or nutrition))</P>
<P># 12 278,724 Topic=((feed or feeding or fed* or food*))</P>
<P># 11 37,433 #10 OR #9 OR #8 OR #7 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1</P>
<P># 10 386 Topic=(("advanced directive*" or "living will*" or "do-not-resuscitate order*"))</P>
<P># 9 412 Topic=(("incurable illness*" or "incurable disease*"))</P>
<P># 8 3,316 Topic=("advanced disease*")</P>
<P># 7 12,963 Topic=(("end-stage disease*" or "end stage disease* or end-stage illness" or "end stage"))</P>
<P># 6 2,135 Topic=(hospice*)</P>
<P># 5 6,392 Topic=((end near/3 life))</P>
<P># 4 1,176 Topic=((terminal* near/6 disease*))</P>
<P># 3 1,527 Topic=((terminal* near/6 ill*))</P>
<P># 2 906 Topic=((terminal* near/6 care*))</P>
<P># 1 14,889 Topic=(palliat*)</P>
<P>
<B>CINAHL (EBSCO)</B>
</P>
<P>S22 S14 AND S21</P>
<P>S21 S15 OR S16 OR S17 OR S18 OR S19 OR S20</P>
<P>S20 (diet or nutrition)</P>
<P>S19 (MH "Food+")</P>
<P>S18 (feed or feeding or fed* or food*)</P>
<P>S17 (MH "Feeding Methods+")</P>
<P>S16 (MH "Diet Therapy+")</P>
<P>S15 (MH "Nutritional Assessment")</P>
<P>S14 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13</P>
<P>S13 ("advanced directive*" or "living will*" or "do-not-resuscitate order*")</P>
<P>S12 ("incurable illness*" or "incurable disease*")</P>
<P>S11 "advanced disease*"</P>
<P>S10 ("end-stage disease*" or "end stage disease* or end-stage illness" or "end stage")</P>
<P>S9 hospice*</P>
<P>S8 (end n3 life)</P>
<P>S7 (terminal* N6 disease*)</P>
<P>S6 (terminal* N6 ill*)</P>
<P>S5 (terminal* N6 care*)</P>
<P>S4 (MH "Terminal Care+")</P>
<P>S3 (MH "Terminally Ill Patients+")</P>
<P>S2 palliat*</P>
<P>S1 (MH "Palliative Care")</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="AFF_15245_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="15245">
<ADDRESS>
<DEPARTMENT>Palliative Care</DEPARTMENT>
<ORGANISATION>St Vincent&#8217;s Private Hospital</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Brisbane</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;0 of studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;0 of studies included in qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;0 of studies included in previous versions of the review&lt;/p&gt;"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;0 of NEW studies included&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;9 of full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;7501 of records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;7501 of records after duplicates removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;10967 of records identified through database searching (2008-2014)&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;0 of additional records identified through other sources&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;7492 of records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;9 of full-text articles excluded, with reasons&lt;/p&gt;&lt;p&gt;0 were RCTs or prospective controlled trials&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>